Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 130
Filter
1.
Mediators Inflamm ; 2021: 6627087, 2021.
Article in English | MEDLINE | ID: mdl-34257517

ABSTRACT

BACKGROUND: Immunoglobulin E (IgE) is the most important promoter of allergic inflammation. However, there are few systematic studies on IgE in age range, genders, disease spectrum, and time regularity. AIM: To screen the common allergens, allergen spectrum, and IgE difference between type 2 inflammatory allergic diseases and other allergic diseases in Weifang, China. METHODS: A retrospective study was performed by estimating patients' clinical data suffering from allergic diseases (urticaria, pollinosis, allergic rhinitis, atopic dermatitis, and bronchial asthma) between May 2019 and April 2020 using an allergen detection kit of Macro-Union Pharmaceutical. RESULTS: 732 of the 1367 patients showed different antigen positive, and the positive rate was 53.5%. The most common allergens were dust mites, mixed fungi, Artemisia pollen, cat/dog dander, and cockroaches. There were 27.0% (369/1367) of the patients with single positive allergen-specific IgE (sIgE), 26.5% (363/1367) with multiple-positive IgE. The total immunoglobulin E (tIgE) levels varied with gender, age, and type of disease. There was a difference in the distribution of allergens between children and adults. A positive correlation between the serum-specific IgE and the corresponding local inhaled allergen density was observed. CONCLUSIONS: In this study, we found that type 2 inflammatory allergic diseases have higher serum IgE and a higher probability of inhaled sIgE positive. According to age, gender, and condition, serological IgE detection of allergens provides new insight into the early diagnosis and prevention of allergic diseases.


Subject(s)
Asthma/blood , Dermatitis/blood , Hypersensitivity/blood , Immunoglobulin E/blood , Rhinitis/blood , Adolescent , Adult , Aged , Allergens/blood , Asthma/immunology , Child , Child, Preschool , China/epidemiology , Dermatitis/immunology , Female , Humans , Hypersensitivity/immunology , Infant , Infant, Newborn , Inflammation , Male , Middle Aged , Reproducibility of Results , Retrospective Studies , Rhinitis/immunology , Young Adult
2.
J Invest Dermatol ; 141(6): 1395-1403, 2021 06.
Article in English | MEDLINE | ID: mdl-33810836

ABSTRACT

Platelets have long been known as mediators of hemostasis and, more recently, as mediators of thromboinflammation, although their physiopathological role has mostly been investigated in the context of disease of internal organs, such as liver and kidney, or systemic disorders. Of late, exciting recent data suggest that platelets may also play a role in inflammation at distal sites such as the skin: recent studies show that platelets, by engaging polymorphonuclear neutrophils (PMNs), contribute to local inflammation in the frequent skin disorder, psoriasis. In an experimental model, systemic depletion of platelets drastically attenuated skin inflammation by preventing PMN infiltration of the skin. A broader role of platelets in different types of skin inflammation is therefore likely, and in this paper, we specifically review recent advances in psoriasis. Special emphasis is given to the crosstalk with systemic platelet effects, which may be of interest in psoriasis-related cardiovascular comorbidities. Furthermore, we discuss the potential for platelet-centered interventions in the therapy for psoriasis.


Subject(s)
Blood Platelets/immunology , Cardiovascular Diseases/immunology , Dermatitis/immunology , Psoriasis/immunology , Skin/pathology , Animals , Blood Coagulation/immunology , Cardiovascular Diseases/blood , Cardiovascular Diseases/epidemiology , Cell Communication/immunology , Comorbidity , Dermatitis/blood , Dermatitis/epidemiology , Dermatitis/pathology , Disease Models, Animal , Humans , Neutrophils/immunology , Psoriasis/blood , Psoriasis/epidemiology , Psoriasis/pathology , Skin/immunology
3.
Eur J Dermatol ; 31(1): 41-47, 2021 Feb 01.
Article in English | MEDLINE | ID: mdl-33586660

ABSTRACT

BACKGROUND: Although polychlorinated biphenyls (PCBs) have been classified as human carcinogens for their association with melanoma, few data are available for other skin lesions. OBJECTIVES: To investigate the prevalence of skin disorders in a highly PCB polluted area in northern Italy, with locally produced food as the main source of human contamination, and evaluate the association between skin lesions and PCB serum levels, taking account of possible confounders. MATERIALS & METHODS: Thirty-three PCB congeners were quantitatively assessed and a total of 189 subjects were equally divided into three groups using the tertiles of total PCB serum concentrations. All subjects underwent a clinical examination and were interviewed on their risk factors and history of skin diseases. RESULTS: No statistically significant difference was found in the prevalence of skin cancer, nevi, pigmentary disorders as well as inflammatory and infectious skin diseases among the three PCB exposure groups. It should be noted that the use of questionnaires to assess subjects' past sun exposure and photoprotection is intrinsically flawed due to random error. CONCLUSION: Our study does not support the hypothesis that chronic PCB exposure, through the ingestion of contaminated food, determines an increased risk of developing skin diseases.


Subject(s)
Environmental Pollutants/blood , Environmental Pollution , Polychlorinated Biphenyls/blood , Skin Diseases/blood , Skin Diseases/epidemiology , Skin Neoplasms/blood , Skin Neoplasms/epidemiology , Aged , Aged, 80 and over , Cross-Sectional Studies , Dermatitis/blood , Dermatitis/epidemiology , Female , Humans , Italy/epidemiology , Male , Middle Aged
4.
J Trace Elem Med Biol ; 65: 126729, 2021 May.
Article in English | MEDLINE | ID: mdl-33610058

ABSTRACT

Despite the knowledge about heavy metals toxicity on humans, its use is widely spread mainly for industrial processes. Chromium is an element that belongs to this group and although it is present in our daily diet, it can also be harmful for humans, causing skin allergies and increasing the risk of lung cancer, among other health effects reported. In this review, we highlight its nutritional role, its toxicokinetic and toxicodynamic in humans, its regulation in the industry and the biomonitoring proposal of this element in blood and urine samples with the aim to control the level of exposure of the workers in military industry and also of the general population.


Subject(s)
Chromium/metabolism , Dermatitis/metabolism , Lung Neoplasms/metabolism , Chromium/adverse effects , Chromium/analysis , Dermatitis/blood , Dermatitis/urine , Environmental Monitoring , Humans , Lung Neoplasms/blood , Lung Neoplasms/urine
5.
J Am Acad Dermatol ; 84(4): 913-920, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33259876

ABSTRACT

BACKGROUND: Psoriasis is associated with increased cardiovascular risk that is not captured by traditional proinflammatory biomarkers. OBJECTIVE: To investigate the relationship between Psoriasis Area and Severity Index, circulating proinflammatory biomarkers, and vascular health in psoriasis. METHODS: In patients with psoriasis and in age and sex-matched controls, 273 proteins were analyzed with the Proseek Multiplex Cardiovascular disease reagents kit and Inflammatory reagents kit (Olink Bioscience), whereas vascular endothelial inflammation and health were measured via direct transcriptomic analysis of brachial vein endothelial cells. RESULTS: In psoriasis, chemokine ligand 20 (CCL20), interleukin (IL) 6, and IL-17A were the top 3 circulating proinflammatory cytokines. Vascular endothelial inflammation correlated with CCL20 (r = 0.55; P < .001) and less so with IL-6 (r = 0.36; P = .04) and IL-17A (r = 0.29; P = .12). After adjustment for potential confounders, the association between CCL20 and vascular endothelial inflammation remained significant (ß = 1.71; P = .02). In nested models, CCL20 added value (χ2 = 79.22; P < .001) to a model already incorporating the Psoriasis Area and Severity Index, Framingham risk, high-sensitivity C-reactive protein, Il-17A, and IL-6 (χ2 = 48.18; P < .001) in predicting vascular endothelial inflammation. LIMITATIONS: Our study was observational and did not allow for causal inference in the relationship between CCL20 and cardiovascular risk. CONCLUSION: We demonstrate that CCL20 expression has a strong association with vascular endothelial inflammation, reflects systemic inflammation, and may serve as a potential biomarker of impaired vascular health in psoriasis.


Subject(s)
Chemokine CCL20/blood , Psoriasis/blood , Adult , C-Reactive Protein/analysis , Comorbidity , Cytokines/blood , Dermatitis/blood , Dermatitis/etiology , Endothelium, Vascular/pathology , Female , Heart Disease Risk Factors , Humans , Interleukin-17/blood , Interleukin-6/blood , Linear Models , Lipids/blood , Male , Middle Aged , Predictive Value of Tests , Psoriasis/complications , Sensitivity and Specificity , Severity of Illness Index , Vasculitis/blood , Vasculitis/etiology , Young Adult
7.
J Dermatol Sci ; 95(1): 2-7, 2019 Jul.
Article in English | MEDLINE | ID: mdl-31272851

ABSTRACT

The human skin is populated by recirculating T cells and skin-sessile resident memory T cells (TRM). Skin TRM are constructed during immune responses against antigens that the host immune system encounters in the skin. TRM persist in the same sites for a long time and play important protective roles in skin immune responses in collaboration with other skin-composing cells such as dendritic cells and keratinocytes. These TRM with strong effector functions possibly also engender skin inflammatory disorders. Since human skin T cells, especially TRM, are phenotypically distinct from T cells in the blood circulation, T cells residing in the skin should be directly investigated, without presuming from the activities of blood T cells, in order to understand the functional characteristics of skin T cells in skin disorders. This review summarizes the features of human skin TRM and reviews the immunopathological involvement of TRM in human skin disorders such as infectious disease, inflammatory skin disease, and malignant skin tumors.


Subject(s)
Dermatitis/immunology , Immunologic Memory , Skin Diseases, Infectious/immunology , Skin Neoplasms/immunology , T-Lymphocytes/immunology , Dermatitis/blood , Dermatitis/pathology , Humans , Skin/immunology , Skin/pathology , Skin Diseases, Infectious/blood , Skin Diseases, Infectious/pathology , Skin Neoplasms/blood , Skin Neoplasms/pathology , T-Lymphocytes/metabolism
10.
Exp Dermatol ; 27(2): 178-184, 2018 02.
Article in English | MEDLINE | ID: mdl-29247486

ABSTRACT

Psoriasis, a chronic inflammatory skin disease, is closely related to systemic metabolism. An elevated body mass index (BMI) is a risk factor for psoriasis; inflammasomes are activated by adipose tissue macrophages in obese subjects. We hypothesized that hyperlipidaemia is involved in the pathogenesis of psoriasis and examined the role of a high-fat diet (HFD) in the development of psoriasis in imiquimod (IMQ)-treated mice. The body weight and serum level of cholesterol were significantly higher in mice fed an HFD than in a regular diet (RD). HFD mice had higher psoriasis skin scores, and the number of neutrophils infiltrating into the lesional skin was elevated. IL-17A mRNA expression was significantly increased in the skin of IMQ-treated HFD mice; the expression of IL-22, IL-23 and TNF-α mRNA was not enhanced. Caspase-1 and IL-1ß were activated in the skin of IMQ-treated HFD mice, and their serum level of IL-17A, TNF-α and IL-1ß was significantly upregulated. Our findings strongly suggest that hyperlipidaemia is involved in the development and progression of psoriasis via systemic inflammation and inflammasome activation.


Subject(s)
Dermatitis/blood , Dermatitis/immunology , Diet, High-Fat , Psoriasis/blood , Psoriasis/immunology , Animals , Body Weight , Cholesterol/blood , Cytokines/metabolism , Disease Models, Animal , Disease Progression , Hyperlipidemias/immunology , Imiquimod , Inflammasomes , Inflammation , Male , Mice , Mice, Inbred C57BL , Neutrophils/immunology , Psoriasis/chemically induced , Skin/pathology
12.
Article in Japanese | MEDLINE | ID: mdl-28603207

ABSTRACT

Nivolumab is a standard recombinant antibody treatment for patients with malignant melanoma (MM), which functions as an immune checkpoint inhibitor by blocking the programmed cell death-1 (PD-1) pathway in T cells. However, it leads to various immune-related adverse events (irAEs), and also exacerbates underlying autoimmune diseases. Herein we report cases of MM with irAE. Case 1: A 69-year-old woman with MM developed destructive thyroiditis resulting in hypothyroidism after 3 doses of nivolumab, and had been treated with thyroid gland auxiliary therapy. Case 2: A 80-year-old man with MM developed an acute onset of hyperthyroidism after 4 doses of nivolumab. Case 3: A 85-year-old woman with MM developed polyradiculoneuropathy resulting in somatosensory disorder and muscle weakness after 2 doses of nivolumab, and had been treated with intravenous immunoglobulin and oral predonisolone (40 mg/day). Case 4: A 77-year-old man with MM developed psoriasiform dermatitis after local injections of IFN-ß and 11 doses of nivolumab. Case 5: Case 2 also developed psoriasiform dermatitis. We analyzed serum levels of inflammatory cytokines in MM patients before/after treatments with nivolumab. All six patients who developed psoriasiform dermatitis with/without anamnesis of psoriasis after treatment with nivolumab, and all seven patients with other irAE exhibited increased serum IL-6 levels after nivolumab treatment, while decreased serum levels of IL-6 were observed in 5 of 7 non-afflicted MM patients. In addition, MM patients who achieved good responses to nivolumab significantly exhibited decreased serum TNF-α levels after nivolumab treatment compared to progressive MM patients.


Subject(s)
Antibodies, Monoclonal/adverse effects , Dermatitis/etiology , Interleukin-6/blood , Psoriasis/etiology , Aged , Aged, 80 and over , Antibodies, Monoclonal/therapeutic use , Dermatitis/blood , Female , Humans , Hyperthyroidism/blood , Hyperthyroidism/etiology , Male , Melanoma/drug therapy , Nivolumab , Polyradiculoneuropathy/blood , Polyradiculoneuropathy/etiology , Programmed Cell Death 1 Receptor/immunology , Psoriasis/blood , T-Lymphocytes/immunology , Thyroiditis/blood , Thyroiditis/etiology , Tumor Necrosis Factor-alpha/blood
13.
Skin Pharmacol Physiol ; 30(1): 24-35, 2017.
Article in English | MEDLINE | ID: mdl-28152530

ABSTRACT

BACKGROUND: Ultraviolet (UV) irradiation is well known to promote inflammation and pigmentation of skin. UVB mainly affects dermatitis and pigmentation. Coffee contains a number of polyphenols, such as caffeic acid (CA) and chlorogenic acid (CGA) but their in vivo bioactivity for photobiology remains unclear. METHODS: C57BL/6j male mice were irradiated with UVB (1.0 kJ/m2/day) for 3 days. Five days after the final session of UVB irradiation, the dorsal skin, ear epidermis, and blood samples were analyzed to investigate the inflammatory factors, melanogenesis factors and related hormones. RESULTS: After the oral administration of CA (100 mg/day) or CGA (100 mg/day) for 8 days, only CA was found to inhibit dermatitis and pigmentation. The pathway by which CA inhibits dermatitis is related to the mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase (ERK)1/2/cAMP response element binding protein (CREB) pathway. Otherwise, the pathway by which CA inhibits pigmentation is related to the activation of the ß-endorphin-µ-opioid receptor and suppresses the cAMP-microphthalmia-associated transcription factor (MITF) pathway. CONCLUSION: It is suggested that the oral administration of CA prevented dermatitis and pigmentation after UVB irradiation in mice.


Subject(s)
Caffeic Acids/pharmacology , Coffee , Dermatitis/prevention & control , Ultraviolet Rays/adverse effects , Adrenocorticotropic Hormone/blood , Animals , Chlorogenic Acid/pharmacology , Dermatitis/blood , Dermatitis/metabolism , Dermatitis/pathology , Male , Mice, Inbred C57BL , Mitogen-Activated Protein Kinases/metabolism , Skin/drug effects , Skin/metabolism , Skin/pathology , Skin/radiation effects , Skin Pigmentation/drug effects , Skin Pigmentation/radiation effects , alpha-MSH/blood , beta-Endorphin/blood
14.
Dermatol Online J ; 23(9)2017 Sep 15.
Article in English | MEDLINE | ID: mdl-29469725

ABSTRACT

Autoimmunity-associated neutrophilic dermatoses are a recently recognized manifestation of connective tissue diseases, in particular, lupus erythematosus. These entities are clinically and sometimes histopathologically distinct from classic neutrophilic dermatoses. We describe a case of an autoimmunity-related neutrophilic dermatosis in a patient with rheumatoid arthritis. In addition to this uncommon association, there was an absence of mature neutrophils and a population of immature histiocytoid granulocytes. This unusual case expands the concept of histiocytoid neutrophilic dermatoses to include those seen in association with autoimmune connective tissue diseases.


Subject(s)
Arthritis, Rheumatoid/complications , Dermatitis/complications , Dermatitis/immunology , Neutrophils , Aged , Dermatitis/blood , Dermatitis/pathology , Granulocytes/pathology , Humans , Leukocyte Count , Male
15.
J Dermatol Sci ; 84(3): 266-271, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27686401

ABSTRACT

BACKGROUND: Atopic dermatitis (AD) is a multifactorial inflammatory skin disease characterized by skin barrier dysfunction, allergic inflammation and intractable pruritus resistant to conventional antipruritic treatments, including H1-antihistamines. Granzymes (Gzms) are a family of serine proteases expressed by cytotoxic T lymphocytes and natural killer cells that have been shown to modulate inflammation. However, the relationship between Gzms and pathology in AD remains unclear. OBJECTIVE: This study assessed the correlation between plasma GzmB levels and severity of pruritus and dermatitis, in AD patients. METHODS: Plasma was collected from 46 patients with AD, 24 patients with psoriasis, and 30 healthy controls. AD severity was assessed with the scoring atopic dermatitis (SCORAD) index, psoriasis severity with the psoriasis area and severity index (PASI), and degree of pruritus by visual analogue scale (VAS) score. GzmA, GzmB and gastrin releasing peptide (GRP) levels were measured by enzyme-linked immunosorbent assays. RESULTS: Plasma GzmB concentrations were significantly higher in patients with AD and psoriasis than in healthy controls. Correlation analyses showed that plasma GzmB concentrations positively correlated with SCORAD and serum levels of severity markers such as thymus and activation-regulated chemokine, and lactate dehydrogenase in AD patients. Moreover, plasma levels of GRP, an itch-related peptide, were higher in patients with AD, positively correlating with VAS score and plasma GzmB level. In addition, plasma GzmB concentration was significantly lower in the treatment group than the untreated group with AD. Meanwhile, there were no correlations among GzmB levels, VAS score and PASI score in patients with psoriasis. In contrast to the results of plasma GzmB, plasma GzmA levels were unchanged among AD, psoriasis and healthy groups, and showed no correlations with VAS score and SCORAD index in patients with AD. CONCLUSION: Plasma GzmB levels may reflect the degree of pruritus and dermatitis in patients with AD.


Subject(s)
Dermatitis, Atopic/blood , Dermatitis/blood , Granzymes/blood , Pruritus/blood , Psoriasis/blood , Adult , Case-Control Studies , Dermatitis/immunology , Dermatitis, Atopic/immunology , Enzyme-Linked Immunosorbent Assay , Female , Gastrin-Releasing Peptide/blood , Gene Expression Regulation , Humans , Inflammation , Killer Cells, Natural/cytology , Male , Middle Aged , Pruritus/immunology , Psoriasis/immunology , T-Lymphocytes, Cytotoxic/cytology
16.
Hautarzt ; 67(1): 27-32, 2016 Jan.
Article in German | MEDLINE | ID: mdl-26530489

ABSTRACT

Due to the increasing incidence of allergies, the importance of allergy diagnostic procedures is growing. In addition to a patient's history and prick, intracutaneous and patch testing, serological testing is an important diagnostic procedure. In recent years, tremendous advances have been made in the area of in vitro allergy tests. In particular, it is possible to predict severity and risk management of food allergies with component-based IgE diagnostic procedures. Even new allergy syndromes have been elucidated at the molecular level.


Subject(s)
Dermatitis/diagnosis , Hypersensitivity/diagnosis , Immunoassay/methods , Molecular Diagnostic Techniques/methods , Serologic Tests/methods , Skin Tests/methods , Dermatitis/blood , Dermatitis/immunology , Humans , Hypersensitivity/blood , Hypersensitivity/immunology
17.
Immunol Cell Biol ; 94(1): 66-78, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26084385

ABSTRACT

Defects in apoptosis can cause autoimmune disease. Loss-of-function mutations in the 'death receptor' FAS impair the deletion of autoreactive lymphocytes in the periphery, leading to progressive lymphadenopathy and systemic lupus erythematosus-like autoimmune disease in mice (Fas(lpr/lpr) (mice homozygous for the lymphoproliferation inducing spontaneous mutation)) and humans. The REL/nuclear factor-κB (NF-κB) transcription factors regulate a broad range of immune effector functions and are also implicated in various autoimmune diseases. We generated compound mutant mice to investigate the individual functions of the NF-κB family members NF-κB1, NF-κB2 and c-REL in the various autoimmune pathologies of Fas(lpr/lpr) mutant mice. We show that loss of each of these transcription factors resulted in amelioration of many classical features of autoimmune disease, including hypergammaglobulinaemia, anti-nuclear autoantibodies and autoantibodies against tissue-specific antigens. Remarkably, only c-REL deficiency substantially reduced immune complex-mediated glomerulonephritis and extended the lifespan of Fas(lpr/lpr) mice. Interestingly, compared with the Fas(lpr/lpr) animals, Fas(lpr/lpr)nfkb2(-/-) mice presented with a dramatic acceleration and augmentation of lymphadenopathy that was accompanied by severe lung pathology due to extensive lymphocytic infiltration. The Fas(lpr/lpr)nfkb1(-/-) mice exhibited the combined pathologies caused by defects in FAS-mediated apoptosis and premature ageing due to loss of NF-κB1. These findings demonstrate that different NF-κB family members exert distinct roles in the development of the diverse autoimmune and lymphoproliferative pathologies that arise in Fas(lpr/lpr) mice, and suggest that pharmacological targeting of c-REL should be considered as a strategy for therapeutic intervention in autoimmune diseases.


Subject(s)
Lupus Erythematosus, Systemic/complications , Lymphatic Diseases/complications , NF-kappa B p50 Subunit/deficiency , NF-kappa B p52 Subunit/deficiency , Proto-Oncogene Proteins c-rel/metabolism , fas Receptor/metabolism , Animals , Autoantibodies/blood , Chemokines/blood , Chemokines/metabolism , Dermatitis/blood , Dermatitis/complications , Dermatitis/immunology , Forkhead Transcription Factors/metabolism , Genotype , Hypergammaglobulinemia/blood , Hypergammaglobulinemia/complications , Immune Tolerance/immunology , Leukocytes/pathology , Longevity , Lupus Erythematosus, Systemic/blood , Lymphatic Diseases/blood , Mice, Inbred C57BL , Mice, Knockout , Mice, Mutant Strains , NF-kappa B p50 Subunit/metabolism , NF-kappa B p52 Subunit/metabolism , Organ Specificity , Splenomegaly/blood , Transcription Factors/metabolism , AIRE Protein
18.
J Pharm Pharmacol ; 67(12): 1623-33, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26709036

ABSTRACT

OBJECTIVES: For several years, protease-activated receptors (PARs) are targets of science regarding to various diseases and platelet aggregation. In the past, a number of publications related to PARs have been published, which refer to a variety of aspects. An important point of view is the inflammation of the skin, which has not been reported in detail yet. This review will provide an overview of the current knowledge on PARs, and in particular, on the involvement of PARs in terms of skin inflammation. KEY FINDINGS: Wound healing is an important step after skin injury and is connected with involvement of PARs and inflammation. An important point in skin inflammation is the coagulation-dependent skin inflammation. SUMMARY: PARs are a special kind of receptors, being activated by proteolytic cleavage or chemical agonists. They may play an important role in various physiological processes. It is shown that the proteases are involved in many diseases for example Parkinson's disease and Alzheimer's disease. The fact, that proteases regulate the coagulation, and are involved in interleukin and cytokine release leads to the conclusion that they are involved in inflammation processes.


Subject(s)
Dermatitis/metabolism , Inflammation Mediators/metabolism , Receptors, Proteinase-Activated/metabolism , Skin/metabolism , Animals , Blood Coagulation , Cytokines/metabolism , Dermatitis/blood , Dermatitis/pathology , Humans , Signal Transduction , Skin/pathology , Wound Healing
19.
J Immunol ; 195(5): 2006-18, 2015 Sep 01.
Article in English | MEDLINE | ID: mdl-26223654

ABSTRACT

Psoriasis patients exhibit an increased risk of death by cardiovascular disease (CVD) and have elevated levels of circulating intermediate (CD14(++)CD16(+)) monocytes. This elevation could represent evidence of monocyte dysfunction in psoriasis patients at risk for CVD, as increases in circulating CD14(++)CD16(+) monocytes are predictive of myocardial infarction and death. An elevation in the CD14(++)CD16(+) cell population has been previously reported in patients with psoriatic disease, which has been confirmed in the cohort of our human psoriasis patients. CD16 expression was induced in CD14(++)CD16(-) classical monocytes following plastic adhesion, which also elicited enhanced ß2 but not ß1 integrin surface expression, suggesting increased adhesive capacity. Indeed, we found that psoriasis patients have increased monocyte aggregation among circulating PBMCs, which is recapitulated in the KC-Tie2 murine model of psoriasis. Visualization of human monocyte aggregates using imaging cytometry revealed that classical (CD14(++)CD16(-)) monocytes are the predominant cell type participating in these aggregate pairs. Many of these pairs also included CD16(+) monocytes, which could account for apparent elevations of intermediate monocytes. Additionally, intermediate monocytes and monocyte aggregates were the predominant cell type to adhere to TNF-α- and IL-17A-stimulated dermal endothelium. Ingenuity Pathway Analysis demonstrated that monocyte aggregates have a distinct transcriptional profile from singlet monocytes and monocytes following plastic adhesion, suggesting that circulating monocyte responses to aggregation are not fully accounted for by homotypic adhesion, and that further factors influence their functionality.


Subject(s)
Dermatitis/immunology , Monocytes/immunology , Psoriasis/immunology , Transcriptome/immunology , Adult , Animals , Cell Adhesion/genetics , Cell Adhesion/immunology , Cell Aggregation/genetics , Cell Aggregation/immunology , Cells, Cultured , Chronic Disease , Coculture Techniques , Dermatitis/blood , Dermatitis/genetics , Disease Models, Animal , Endothelial Cells/immunology , Endothelial Cells/metabolism , Female , Humans , Keratinocytes/metabolism , Lipopolysaccharide Receptors/genetics , Lipopolysaccharide Receptors/immunology , Lipopolysaccharide Receptors/metabolism , Male , Mice, Transgenic , Microscopy, Confocal , Middle Aged , Monocytes/metabolism , Psoriasis/blood , Psoriasis/genetics , Receptor, TIE-2/genetics , Receptor, TIE-2/metabolism , Receptors, IgG/genetics , Receptors, IgG/immunology , Receptors, IgG/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Young Adult
20.
Autoimmunity ; 48(4): 259-66, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25352178

ABSTRACT

Ankylosis is a major pathological manifestation of spondyloarthropathy. The aim of this study was to evaluate the effects of anti-IL-17 therapy on spontaneous ankylosing enthesitis in mice. In this study, we used male DBA/1 mice as a spontaneous ankylosis model. Serum IL-17 concentrations were determined using enzyme-linked immunosorbent assay. Male DBA/1 mice from different litters were mixed and caged together preceding the treatment at 10 weeks (wk) of age (prophylaxis) or 21 wk of age (intervention). Treatment with anti-IL-17 antibodies or saline was initiated after caging in groups of mice and administered weekly. The onset of tarsal ankylosis was assessed by ankle swelling and histopathological examination. Pathological changes and mRNA expression levels were assessed in joints and ears obtained at the experimental end-point. We found that circulating IL-17 increased with the onset of ankylosis in male DBA/1 mice, coinciding with the onset of dermatitis. The symptoms of dermatitis corresponded to the pathological characteristics of psoriasis: acanthosis with mild hyperkeratosis, scaling, epidermal microabscess formation and augmented expression of K16, S100A8 and S100A9. Prophylactic administration of anti-IL-17 antibodies significantly prevented the development of both ankylosis and dermatitis in male DBA/1 mice caged together. On the other hand, administration of anti-IL-17 antibodies after disease onset had a lesser but significant effect on ankylosis progression but did not affect dermatitis progression. In conclusion, IL-17 is a key mediator in the pathogenic process of tarsal ankylosis and psoriasis-like dermatitis in male DBA/1 mice caged together. Thus, IL-17 is a potential therapeutic target in ankylosing enthesitis and psoriasis in humans.


Subject(s)
Ankylosis/metabolism , Ankylosis/pathology , Antibodies, Monoclonal/pharmacology , Dermatitis/metabolism , Dermatitis/pathology , Interleukin-17/metabolism , Psoriasis/metabolism , Psoriasis/pathology , Animals , Ankylosis/drug therapy , Ankylosis/prevention & control , Antibodies, Monoclonal/administration & dosage , Dermatitis/blood , Dermatitis/drug therapy , Dermatitis/prevention & control , Disease Models, Animal , Disease Progression , Interleukin-17/antagonists & inhibitors , Interleukin-17/blood , Interleukin-6/blood , Interleukin-6/metabolism , Male , Mice , Premedication , Psoriasis/drug therapy , Psoriasis/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL
...